Valuation: Fennec Pharmaceuticals Inc.

Market Cap 381M 342M 316M 286M 535M 36.3B 541M 3.78B 1.51B 19B 1.43B 1.4B 60.31B P/E 2026 *
36.2x
P/E 2027 * 11x
Enterprise Value 381M 342M 316M 286M 535M 36.3B 541M 3.78B 1.51B 19B 1.43B 1.4B 60.31B EV / Sales 2026 *
5.25x
EV / Sales 2027 * 3.7x
Free-Float
78.7%
Yield 2026 *
-
Yield 2027 * -
1 day+2.35%
1 week+4.72%
Current month+2.07%
1 month-0.73%
3 months+9.36%
6 months+62.24%
Current year+41.17%
1 week 9.93
Extreme 9.93
10.89
1 month 9.87
Extreme 9.87
10.89
Current year 5.65
Extreme 5.65
13.25
1 year 5.65
Extreme 5.65
13.25
3 years 3.96
Extreme 3.96
13.25
5 years 3.82
Extreme 3.8219
13.25
10 years 1.64
Extreme 1.6439
14.99
Manager TitleAgeSince
Chief Executive Officer 64 2024-08-15
Director of Finance/CFO 51 2010-01-05
Chief Tech/Sci/R&D Officer 51 2024-10-27
Director TitleAgeSince
Director/Board Member 72 2011-08-24
Chairman 69 2015-12-08
Director/Board Member 70 2016-08-09
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Free

Executive/Senior Manager

2,326 0.0066%
10/12/26 Free

Chief Executive Officer

2,224 0.0063%
10/12/26 Free

Chief Financial Officer

3,846 0.0110%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+4.72%+24.09%+58.92% 372M
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.37%+1.78%+38.99%+74.66% 402.79B
Weighted average by Cap. +0.25%+1.55%+44.50%+89.01%

Financials

2026 *2027 *
Net sales 72.56M 65.1M 60.19M 54.51M 102M 6.91B 103M 720M 287M 3.62B 272M 267M 11.48B 103M 92.51M 85.53M 77.46M 145M 9.82B 146M 1.02B 407M 5.14B 387M 379M 16.31B
Net income 10.48M 9.4M 8.69M 7.87M 14.71M 998M 14.89M 104M 41.4M 522M 39.32M 38.49M 1.66B 35.13M 31.52M 29.14M 26.39M 49.3M 3.35B 49.9M 348M 139M 1.75B 132M 129M 5.56B
Net Debt - -
Projected Income Statement - Annual - Fennec Pharmaceuticals Inc.
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
26-10-28 US$10.87 +2.35% 149,543
26-10-27 US$10.62 +4.63% 93,186
26-10-26 US$10.15 +0.69% 115,942
26-10-23 US$10.08 -2.33% 70,820
26-10-22 US$10.32 -0.58% 104,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Fennec Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.87USD
Average target price
17.67USD
Spread / Average Target
+62.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fennec Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. FENC Stock